MICROTOMES MARKET ANALYSIS

Microtomes Market, by Equipment Type (Instruments (Rotary Microtome, Vibrating Microtome, Cryostat Microtome, Freezing Microtome, and Others) and Accessories), by Technology/Interventions (Fully Automated Microtomes, Semi-automated Microtomes, and Manual Microtomes), by Application (Disease Diagnosis and Medical Research), by End User (Hospitals, Ambulatory Surgical Centers, Research Centers, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

Published In : Jun 2023
Code : CMI3783
Pages :176
Formats :
Excel and PDF
Industry : Medical Devices

Market News

Global Microtomes Market: Key Developments

On June 1, 2023, Myriad Genetics, Inc. is genetic testing and precision medicine company based in Salt Lake City, Utah, United States, launched new studies and expansion of its Precise Oncology Solutions portfolio at the 2023 American Society of Clinical Oncology (ASCO).

In May 2022, United Rheumatology, a rheumatology care management organization empowering rheumatologists to advance the standard of care and education, advocacy, and research organization for people living with cancer disease, announced a partnership with creaky joints is a leading support, education, advocacy, and research organization for people living with arthritis and rheumatic disease to develop the Cancer Wellness Center, a digital resource aimed at aiding those living with cancer.

On March 22, 2023, F. Hoffmann-La Roche Ltd (Roche), a biotechnology company that develops drugs and diagnostics to treat major diseases, announced that it had entered into a collaboration with Eli Lilly and Company is pharmaceutical company headquartered in U.S., to support the development of Roche’s Elecsys Microtomes.

In March 2022, Invitae, a medical genetics company, announced full access to its Personalized Cancer Monitoring (PCMTM) platform to help detect minimal or molecular residual disease (MRD) in patients with solid tumors. Invitae PCM uses a novel set of personalized assays based on a patient's tumor to detect circulating tumor DNA (ctDNA) in blood, offering the ability to perform risk stratification, response assessment to treatment, and detection of cancer recurrence, based on recent studies.